Sep. 12, 2014, 11:43 AM
- Arrrayit Corp. (OTCQB:ARYC +1.6%) settles its legal dispute with Avant Diagnostics by mutual agreement. Arrayit will maintain its exclusive right to manufacture OvaDx for Avant until such time as the rights are sold to a third party. Avant's outstanding invoice of $1.55M due Arrayit will be settled by the issuance of 10M Avant shares to Arrayit. The companies will also swap 10M shares between the two.
ARYC vs. ETF Alternatives
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides it specialized equipment, tools, microarray... More
Other News & PR